Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride Effects on Brain Reward Processing in MDD
NCT05347199Phase 1Completed
- Sponsor
- Simone Grimm
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amisulpride in major depressive disorder (MDD) (4 arms), sponsored by Simone Grimm. Primary endpoint: BOLD fMRI parameter estimates during MID task. Started May 2022; status: completed.
02
Drugs
amisulpride
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05347199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347199.